☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
SpringWorks
SpringWorks Published P-III Trial (DeFi) Results of Nirogacestat for Desmoid Tumors in the NEJM
March 9, 2023
SpringWorks Reports the Completion of NDA Submission to the US FDA for Nirogacestat to Treat Desmoid Tumors
December 28, 2022
SpringWorks Entered into an Expanded Non-Exclusive License Agreement with GSK for Nirogacestat + Blenrep to Treat Multiple Myeloma
September 9, 2022
SpringWorks Entered into a Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat + REGN5458 fo...
April 20, 2022
SpringWorks Completes an Enrollment of Mirdametinib in P-IIb ReNeu Trial for the Treatment of NF1-Associated Plexiform Neurofibrom...
November 29, 2021
PharmaShots Weekly Snapshots (October 18 - 22, 2021)
October 22, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.